reta buyout
「reta buyout」熱門搜尋資訊
「reta buyout」文章包含有：「Acquisition|REATAPHARMACEUTICALSINC」、「BiogenAnnounces$7.3BillionAcquisitionOfReata...」、「BiogenCompletesAcquisitionofReataPharmaceuticals」、「BiogentoAcquireReataPharmaceuticals」、「BiogentobuyReatafor$6.5billiontobulkupraredisease...」、「HowBiogenoutbidarival'large」、「ReatashareholdersclearbuyoutdealwithBiogen」、「ReataStockSurges.BiogenIsBuyingItfor$7.3Billionin...」
查看更多
Acquisition | REATA PHARMACEUTICALS INC
https://www.solactive.com
Due to the acquisition of REATA PHARMACEUTICALS INC-A by BIOGEN INC, the following treatment will be applied to the following indices: REATA ...
Biogen Announces $7.3 Billion Acquisition Of Reata ...
https://www.investors.com
Biogen (BIIB) announced Friday it has agreed to acquire Reata Pharmaceuticals (RETA) for about $7.3 billion, boosting biopharmaceutical company Biogen's drug ...
Biogen Completes Acquisition of Reata Pharmaceuticals
https://investors.biogen.com
Biogen Inc. (Nasdaq: BIIB) – has completed the acquisition of Reata Pharmaceuticals, Inc. (Nasdaq: RETA), a company focused on developing therapeutics.
Biogen to Acquire Reata Pharmaceuticals
https://investors.biogen.com
Biogen has agreed to acquire Reata for $172.50 per share in cash, reflecting an enterprise value of approximately $7.3 billion.
Biogen to buy Reata for $6.5 billion to bulk up rare disease ...
https://www.reuters.com
Biogen agreed to buy rare disease drugmaker Reata Pharmaceuticals for nearly $6.5 billion, the first large acquisition under new CEO ...
How Biogen outbid a rival 'large
https://www.fiercepharma.com
Biogen's $7.3 billion buyout of Skyclarys-maker Reata Pharmaceuticals surprised some industry watchers last month.
Reata shareholders clear buyout deal with Biogen
https://seekingalpha.com
Reata Pharmaceuticals (RETA) said that its shareholders approved its previously disclosed acquisition by Biogen (BIIB) at a special meeting ...
Reata Stock Surges. Biogen Is Buying It for $7.3 Billion in ...
https://www.barrons.com
Biogen will acquire Reata for $172.50 a share in cash, expanding its portfolio of neuromuscular disease treatments.